Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
American University of Beirut
Effective rituximab treatment of B-cell PLL reported
June 26th, 2004
Effective treatment of B-cell PLL with rituximab has been reported. Hematologists in Lebanon described "a patient with B-cell prolymphocytic leukemia (PLL) who was treated successfully with the monoclonal anti-CD20 antibody (rituximab)." "The patient had recurrent infections due to relative neutropenia, secondary to bone marrow infiltration," noted Y.A. Mourad and coauthors at the American University in Beirut. "After treatment with monoclonal anti-CD20 antibodies (rituximab) 375 mg/m2 weekly for 4 weeks, complete remission was obtained." "It was documented by normalization of peripheral blood counts, disappearance of...
Source: Law & Health Weekly (2004-06-26)
|
